Share on StockTwits
 

Regeneron Pharmaceuticals (NASDAQ:REGN) Insider George Yancopoulos sold 88,987 shares of the stock on the open market in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $320.33, for a total value of $28,505,205.71. Following the completion of the transaction, the insider now directly owns 1,068,343 shares of the company’s stock, valued at approximately $342,222,313. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on REGN shares. Analysts at Oppenheimer downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. They now have a $325.00 price target on the stock, up previously from $310.00. They noted that the move was a valuation call. Separately, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $344.00 to $348.00 in a research note on Thursday. Finally, analysts at Goldman Sachs raised their price target on shares of Regeneron Pharmaceuticals from $353.00 to $383.00 in a research note on Thursday. They now have a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Buy” and an average price target of $315.85.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.56% during mid-day trading on Thursday, hitting $321.4401. 665,141 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $154.16 and a 52-week high of $327.54. The stock’s 50-day moving average is $284.0 and its 200-day moving average is $280.2. The company has a market cap of $31.573 billion and a P/E ratio of 46.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported $2.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the prior year, the company posted $1.47 earnings per share. The company’s quarterly revenue was up 47.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $6.21 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.